Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report of Berlin-Frankfurt-M ünster study group.

Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report of Berlin-Frankfurt-Münster study group. Haematologica. 2018 Aug 09;: Authors: Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M Abstract Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia have poor survival. We evaluated Gemtuzumab Ozogamicin (CD33-targeted drug) used on compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia-Berlin-Frankfurt-Munster studies and identified 76 patients (<18 years) with highly-advanced and pretreated acute myeloid leukemia [refractory de novo acute myeloid leukemia (n=10), de novo acute myeloid leukemia refractory to relapse (1st early: n=41; 1st late: n=10; 2nd or more: n=10), and secondary acute myeloid leukemia (n=5)]. At doses of 2.5-10 mg/m,2, Gemtuzumab Ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabine (47%), or others (6%). Most common grade 3/4 adverse events were infections or febrile neutropenia (78% of severe adverse events), infusion-related immunologic reactions (6%), and gastrointestinal symptoms (5%). Three patients experienced veno-occlusive disease (one fatal due to exacerbation of a preexisting cardiomyopathy). Sixty-four percent received subsequent hematopoietic stem cell transp...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research